It was a pleasure to meet with Prof. Maria-Antonietta D’Agostino (Versailles-Saint-Quentin University and University Hospital Ambroise Paré, Boulogne-Billancourt, France) to discuss her study investigating the responsiveness of the global OMERACT-US enthesitis score in the ULTIMATE clinical study.
The abstract ‘Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the phase III randomised ULTIMATE study.‘ (OP0226), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What are the prevalence, underlying causes and clinical consequences of enthesitis in psoriatic arthritis? (0:38)
- What is the rationale for developing composite enthesitis scores? (2:11)
- Could you give us an overview of the Outcome Measures in Rheumatology Initiative (OMERACT-US) enthesitis scores that you investigated? (3:29)
- Could you tell us a little about the ULTIMATE clinical study and its findings in terms of the OMERACT-US enthesitis score? (5:21)
- What further studies are necessary to validate the OMERACT-US enthesitis scores? (6:42)
Disclosures: Maria-Antonietta D’Agostino has received speaker and/or consultancy fees from Abbvie, BMS, Janseen, Eli-Lilly, Galapagos, and Novartis.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
